Gilead to raise price for new hepatitis C drug above $84,000

September 12, 2014 10:56 PM

16 0

LOS ANGELES (Reuters) - The next generation version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

Gregg Alton, Gilead's executive vice president of corporate and medical affairs, declined to give an exact price for the new medicine, the first all-oral treatment for the virus which is expected to launch next month.

Read more

To category page